Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has begun recruitment for its second Phase 1 clinical trial of topical TDM-105795 in patients with Androgenetic Alopecia (AGA).
TechnoDerma has recently announced the appointment of Ms. Lu Jiandong as the Chief Financial Officer of the Company.
TechnoDerma announced the appointment of key members of the Scientific Advisory Board, Professor Xiang Leihong, a dermatologist at Fudan University School of medicine, Dr. John Mao, a senior drug R & D expert in the San Francisco Bay area, Professor G
TDM-105795 is the Lead Small Molecule Drug in Topical Formulation
Established in 2014, Technoderma is a leader in the research and development of innovative drugs for skin indications. The success of this round of financing provides a strong support for the company to rapidly advance the preclinical research and
From left to right: Wenkui Fang,Ph.D, Zengquan Wang,Ph.D and Guanqun Li,M.D.Ph.D.
TechnoDerma has built a number of dermatological disease pipelines through independent R&D and license-in. The company is gradually growing into a globally-positioned innovative drug research and development company specialized in dermatology. TechnoD
On July 1, 2016, TechnoDerma announced the completion of a multi-million yuan Angel round of financing. The completion of financing marks the official launch of the startup company and its innovative small molecule drug discovery program for the treatment
